Senti Biosciences Names New CEO, Board Changes
Ticker: SNTI · Form: 8-K · Filed: May 17, 2024 · CIK: 1854270
Sentiment: neutral
Topics: leadership-change, executive-appointment, board-changes
TL;DR
New CEO at Senti Bio, Miller out. Roth is CMO.
AI Summary
Senti Biosciences, Inc. announced on May 14, 2024, a series of executive and board changes. Dr. Philip P. Sia has been appointed as the new Chief Executive Officer and a member of the Board of Directors. Additionally, Dr. Timothy J. Miller has resigned from his roles as CEO and board member, effective May 14, 2024. The company also appointed Dr. Jonathan M. Roth as Chief Medical Officer.
Why It Matters
The appointment of a new CEO and changes in leadership can signal a shift in strategic direction or operational focus for the company.
Risk Assessment
Risk Level: medium — Leadership changes can introduce uncertainty regarding future strategy and execution.
Key Players & Entities
- Senti Biosciences, Inc. (company) — Registrant
- Philip P. Sia (person) — Newly appointed CEO and Board Member
- Timothy J. Miller (person) — Resigned CEO and Board Member
- Jonathan M. Roth (person) — Newly appointed Chief Medical Officer
- May 14, 2024 (date) — Effective date of changes
FAQ
Who has been appointed as the new CEO of Senti Biosciences, Inc.?
Dr. Philip P. Sia has been appointed as the new Chief Executive Officer.
When did the leadership changes become effective?
The changes were effective as of May 14, 2024.
Who has resigned from their position as CEO?
Dr. Timothy J. Miller has resigned from his role as CEO.
Has Senti Biosciences appointed a new Chief Medical Officer?
Yes, Dr. Jonathan M. Roth has been appointed as Chief Medical Officer.
What is the filing date of this 8-K report?
The filing date is May 17, 2024.
Filing Stats: 1,210 words · 5 min read · ~4 pages · Grade level 10.7 · Accepted 2024-05-17 17:17:02
Key Financial Figures
- $0.0001 — ch registered Common Stock, par value $0.0001 per share SNTI The Nasdaq Capital Marke
- $490,000 — ly entitled to an annual base salary of $490,000, a signing bonus of $90,000, and a disc
- $90,000 — salary of $490,000, a signing bonus of $90,000, and a discretionary annual target bonu
Filing Documents
- snti-20240514.htm (8-K) — 30KB
- 0001854270-24-000061.txt ( ) — 156KB
- snti-20240514.xsd (EX-101.SCH) — 2KB
- snti-20240514_lab.xml (EX-101.LAB) — 22KB
- snti-20240514_pre.xml (EX-101.PRE) — 13KB
- snti-20240514_htm.xml (XML) — 3KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. SENTI BIOSCIENCES, INC. Date: May 17, 2024 By: /s/ Timothy Lu, M.D., Ph.D. Name: Timothy Lu, M.D., Ph.D. Title: Chief Executive Officer